-+ 0.00%
-+ 0.00%
-+ 0.00%

CANADA’S DRUG AGENCY ISSUES RECOMMENDATION TO REIMBURSE YORVIPATH® (PALOPEGTERIPARATIDE INJECTION) WITH CONDITIONS FOR ELIGIBLE ADULTS WITH CHRONIC HYPOPARATHYROIDISM

Reuters·09/03/2026 20:08:37

Please log in to view news